γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

May 30, 2028

Conditions

LeukemiaMyeloidAcute

Interventions

BIOLOGICAL

Gamma-Delta T cell injection

Experimental group: Peripheral intravenous infusion of γδ T cells

OTHER

Standard prophylactic treatment

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY